Elizabeth Tan-Chiu, MD
Hematology & Oncology · Tampa, FLNPI 1538113931
Payments from drug & device makers
Across 51 payments — averaging $238.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$7K
- Puma Biotechnology, Inc.$3K
- Eli Lilly$1K
- AstraZeneca$239
- Takeda Pharmaceuticals U.S.A., Inc.$136
- Lilly USA, LLC$121
- plus $691 from 22 others
What the payments were for
- Consulting fees$1,25050%
- Food & beverage$1,24150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 8 | $6,576 |
| Puma Biotechnology, Inc. | 1 | $3,160 |
| Eli Lilly | 1 | $1,250 |
| AstraZeneca | 7 | $239 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $136 |
| Lilly USA, LLC | 1 | $121 |
| Novocure Inc. | 1 | $78 |
| Pfizer | 1 | $63 |
| Myriad Genetic Laboratories, Inc. | 1 | $57 |
| Sanofi | 3 | $54 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $47 |
| Bristol Myers Squibb | 2 | $42 |
| Boehringer Ingelheim | 2 | $38 |
| E.r. Squibb & Sons, L.L.C. | 2 | $36 |
| Bayer | 2 | $34 |
| EMD Serono, Inc. | 1 | $25 |
| Astellas Pharma US Inc | 1 | $24 |
| Daiichi Sankyo Inc. | 1 | $24 |
| Rigel Pharmaceuticals, Inc. | 1 | $23 |
| Genentech USA, Inc. | 1 | $21 |
| Johnson & Johnson | 1 | $20 |
| Merck | 1 | $18 |
| EUSA Pharma (US) LLC | 1 | $16 |
| Tolmar Pharmaceuticals, Inc. | 1 | $15 |
| Agios Pharmaceuticals, Inc. | 1 | $15 |
| Partner Therapeutics, Inc. | 1 | $14 |
| Amgen | 1 | $14 |
| Secura Bio, Inc. | 2 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,173 in reported general payments places this provider in the 45th percentile of 694 hematology & oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prochlorperazine Maleate | 16 | $348 |
| Anastrozole | 12 | $289 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Tampa
- Julio ChavezTampa$16.4M
- Frederick LockeTampa$12.8M
- Richard KimTampa$8.5M
- David SallmanTampa$7.2M
- Andrew BrohlTampa$6.5M
- Bijal ShahTampa$5.7M
- Jonathan ChatzkelTampa$4.2M
- Sonam PuriTampa$3.9M
- Hatem SolimanTampa$3.7M
- Iman ImaniradTampa$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.